Skip to main content

Ustekinumab News (Page 2)

Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis

Horsham, Pa., October 13, 2017 ― Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) for the t...

FDA Approves Stelara (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn's Disease

HORSHAM, Pa., Sept. 26, 2016 /PRNewswire/ – Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of moderately...

Stelara (ustekinumab) Receives FDA Approval to Treat Active Psoriatic Arthritis

HORSHAM, Pa., Sept. 23, 2013 /PRNewswire/ – Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) alone or in combination with...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Crohn's Disease, Crohn's Disease - Acute, Psoriasis, Plaque Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, Ulcerative Colitis - Active

Related drug support groups

Stelara

Ustekinumab patient information at Drugs.com